Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies

Christopher O Barnes; Claudia A Jette; Morgan E Abernathy; Kim-Marie A Dam; Shannon R Esswein; Harry B Gristick; Andrey G Malyutin; Naima G Sharaf; Kathryn E Huey-Tubman; Yu E Lee; Davide F Robbiani; Michel C Nussenzweig; Anthony P West; Pamela J Bjorkman.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-273920

Documentos relacionados

  1. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
  2. Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies.
  3. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
  4. The antigenic anatomy of SARS-CoV-2 receptor binding domain.
  5. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
  6. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.
  7. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
  8. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.
  9. Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes.
  10. Elucidating important structural features for the binding affinity of spike - SARS-CoV-2 neutralizing antibody complexes.